Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders' Deficiency (Parenthetical)

v3.7.0.1
Consolidated Statements of Changes in Stockholders' Deficiency (Parenthetical) - Series C Convertible Preferred Stock [Member] - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Gross proceeds for sale of series C convertible preferred stock $ 1,367,120 $ 1,930,000
Sale of Series C convertible preferred stock, issuance costs 211,835 264,720
Sale of Series C convertible preferred stock, cash 150,383  
Sale of Series C convertible preferred stock, non-cash 61,452  
Issuance of warrants $ 178,414 $ 168,316